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ABSTRACT
Individuals with migraine often have recurrent, painful symptoms, and symptomatic treatments have detrimental 
side effects and do not prevent further attacks. Studies indicate that riboflavin can be used to decrease headache 
frequency and lessen the need for symptomatic treatment. Mitochondrial dysfunction may play a role in migraine 
pathogenesis by interfering with oxygen metabolism. Daily doses of riboflavin, vitamin B2, may improve mitochon-
drial function by increasing the reserve of brain mitochondrial energy, and there are minimal side effects with daily 
treatment. However, there is a need for further randomized, double-blind controlled studies to determine the effec-
tive dose. Although riboflavin may not fully eliminate migraine nor take effect for several months, riboflavin is a 
promising prophylactic agent with minimal adverse effects that may significantly reduce the frequency of migraine.
INTRODUCTION
Importance Of Prophylactic Treatment For Migraine
N
o perfect treatment exists for many individu-
als with migraine, who often have recur-
ring, long-lasting, painful symptoms. With a 
prevalence of 18% in women and 6% in men 
in the United States, migraine is extremely common 
(Lipton and Stewart 1993; Bianchi et al. 2004; Boehnke 
et al. 2004). The use of frequent symptomatic treatment 
without effective prophylactic medications may lead 
to more-frequent headaches and medication-overuse 
headache, which can significantly affect the quality 
of life. Symptomatic medication for migraine includes 
triptans, NSAIDs, and ergotamine (Bianchi et al. 2004). 
Preventive medications include beta blockers, topira-
mate, flunarizine, tricyclic antidepressants, and valproic 
acid (Bianchi et al. 2004; Schurks et al. 2008). However, 
many of these treatments have significant side effects 
that may limit use. Lifestyle changes, including improved 
sleep hygiene, more exercise, decreased stress, and mini-
mizing foods that trigger migraine, may also play a 
noteworthy role in migraine management (Schurks et 
al. 2008; Sun-Edelstein and Mauskop 2009).
While symptomatic treatments may alleviate acute epi-
sodes, they typically do not alter the disease course or 
decrease the frequency of future episodes. Riboflavin 
is just one of a bevy of “natural” treatments or herbal 
remedies used for migraine prophylaxis that may include 
magnesium, feverfew, petasites hybridus, coenzyme 
Q10, alpha lipoic acid, valerian root, ginger, eicosapen-
taenoic acid, and acupuncture (Maizels et al. 2004; Sun-
Edelstein and Mauskop 2009). If patients want to use 
a “natural” treatment for migraine prophylaxis with 
potential benefits and few risks, they should be encour-
aged to use a treatment that is sufficiently studied in 
terms of safety and efficacy; some treatments may be 
less represented in the literature. This review was per-
formed in order to evaluate the efficacy of riboflavin as 
a prophylactic treatment for migraine as reported in the 
literature.
Pathophysiology: Migraine, Mitochondria, And 
Riboflavin
Although the pathogenesis of migraine has not been 
fully elucidated, two pathways by which migraine may 
evolve are through mitochondrial dysfunction and 
through abnormal cortical information processing, both 
leading to activation of a hyperexcitable trigeminovas-
cular system (Sandor et al. 2000). Mitochondrial dysfunc-
tion may play a role in migraine pathogenesis by altering 
oxygen metabolism. Research has indicated that individ-
uals with migraine have decreased mitochondrial phos-
phorylation potential interictally (Bianchi et al. 2004).
Daily doses of riboflavin may improve mitochondrial 
function by increasing the reserve of brain mitochon-
drial energy (Sandor et al. 2000; Maizels et al. 2004). 
Riboflavin is a precursor for substances important for cell 
energy and stability, such as flavin mononucleotides and 
flavin adenine dinucleotide involved in oxidation-reduc-
tion reactions (MacLennan et al. 2008; Sun-Edelstein and 
Mauskop 2009). Riboflavin, at 100 mg/day, has also been 
used in treatment of mitochondrial disorders including 
MELAS (mitochondrial encephalomyopathy, lactic aci-
dosis, and stroke-like episodes) and other mitochondrial 
myopathies (Silberstein and Goadsby 2002; MacLennan 
et al. 2008).
In a study of 64 patients given 400 mg of riboflavin daily 
for four months, each individual was genotyped for mito-
chondrial DNA haplotypes. The different haplogroups 
seem to have some distinct characteristics, especially 
with regard to metabolic activity. Specificially, haplotype 
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H may be more metabolically active and exhibit a higher 
level of mitochondrial oxidative phosphorylation than 
non-H haplotypes (Di Lorenzo et al. 2009). Individuals in 
the non-H haplotype group responded to riboflavin bet-
ter than those in the H haplotype group (77% responder 
rate vs. 44.8%) in terms of decreasing attack frequency, 
and this difference was significant. The difference in 
metabolic activity between the haplotypes may contrib-
ute to the varying response to riboflavin (Di Lorenzo et 
al. 2009). Specifically, it has been hypothesized that the 
higher metabolic activity in the H haplogroup may be 
protective against migraine at baseline, while the non-H 
haplogroup may be more susceptible to migraine and 
may, in turn, benefit more from the riboflavin treat-
ment (Di Lorenzo et al. 2009).
METHODS
A search was performed using the terms “riboflavin” 
and “migraine” in PubMed. All search terms were lim-
ited to the English language. Studies included in this 
review consisted of prospective clinical trials using ribo-
flavin prophylaxis in humans. Studies involving ribo-
Table 1
Study Year
Placebo-
controlled
Age
Number 
of 
patients
Riboflavin 
dose
Treatment 
duration
Outcome 
measure
Findings
Schoenen 
et al. 
1998 Yes
Age 
range: 18 
to 65
55
400 mg/
day
3 months
Decrease in attack 
frequency 
NNT= 
2.3;statistically 
significant
Decrease in 
headache days
NNT=2.8; 
statistically 
significant 
Reduction in 
headache intensity
Not statistically 
significant
Boehnke 
et al.
2004 No
Average 
age 52
23
400 mg/
day
3 to 6 
months
Reduction 
in migraine 
frequency
NNT = 3.1; From 
4 to 2 days/ 
month; statistically 
significant
Decreased use of 
“abortive drugs”
From 7 to 4.5 units/
month; statistically 
significant
Reduction in # of 
headache hours
Decreased by 44%; 
Not statistically 
significant
Reduction in 
headache intensity
Not statistically 
significant
Maizels et 
al.
2004 No 
Average 
age 47
49 25 mg/day 3 months
50% or greater 
reduction in 
migraine
Statistically 
significant
50% or greater 
reduction in 
migraine days
Statistically 
significant 
50% or greater 
decrease in 
migraine index
Statistically 
significant
MacLennan 
et al.
2008 Yes
Average 
age 11
48
200 mg/
day
12 weeks
50% or greater 
reduction in 
the number of 
migraine attacks 
per 4 weeks
Not significant
50% or greater 
reduction 
in migraine 
frequency
Not significant
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flavin combined with other prophylactic agents were 
excluded, as were studies that were not accessible. Four 
studies met inclusion criteria. 
In a randomized trial by Schoenen et al. of 55 patients 
given 400 mg of riboflavin per day for three months, 
attack frequency and headache days were significantly 
reduced compared to placebo, with the number needed 
to treat reported as 2.3 for headache days and 2.8 for 
attack frequency (Schoenen et al. 1998). In an open-label 
study of 23 migraineurs treated with riboflavin (400 mg 
for three to six months), migraine frequency was sig-
nificantly reduced, from four to two days per month. 
Additionally, the use of “abortive drugs” decreased from 
seven to four units per month. Although the number of 
headache hours decreased by 44%, this was not statis-
tically significant. Furthermore, no change in headache 
intensity was found (Boehnke et al. 2004).
In a randomized, double-blind study of 49 patients 
given a daily compound of riboflavin 400 mg, magne-
sium 300 mg, and feverfew 100 mg versus a “placebo” 
of 25 mg riboflavin for three months, there was no dif-
ference between the groups for reduction of migraine 
frequency, decrease in migraine days, migraine index, 
or triptan doses. Rather, both groups, the combination 
compound and the riboflavin 25 mg that was intended 
to serve as the placebo, experienced significant decrease 
in migraine, migraine days, and migraine index. The 
response exhibited by the “placebo” of riboflavin 25mg 
is a greater response than has been typically shown by 
placebo in previous migraine studies, which may indicate 
that this lower dose of riboflavin is protective against 
migraine (Maizels et al. 2004). However, a true placebo 
was not used.
Riboflavin has been studied in children, with conflict-
ing results. Some retrospective studies showed signifi-
cant decreases in frequency and intensity of attacks, but 
fewer randomized studies exist (Condo et al. 2009). A 
randomized, double-blind study of 48 patients evaluat-
ing efficacy of riboflavin (200 mg/day for 12 weeks) in 
migraine prophylaxis in children showed less-than-prom-
ising results. There were no significant differences in the 
primary outcome or the number of patients achieving 
a 50% or greater reduction in the number of migraine 
attacks, nor was there a significant difference in any of 
the secondary outcomes, such as migraine severity or 
migraine duration (MacLennan et al. 2008). The results 
of this study indicate that riboflavin may not be appro-
priate prophylaxis for children with migraine.
DISCUSSION
There has been only one placebo-controlled study of 
riboflavin in adults with migraine, which found that 
riboflavin decreased attack frequency and number of 
headache days (Schoenen et al. 1998).
There are many advantages to riboflavin, which include 
water solubility, good tolerability, and no long-term tox-
icity . Negative aspects of the treatment include daily 
medication, questionable efficacy, potential yellow/
orange urine discoloration, and possible nausea, diar-
rhea, and polyuria (MacLennan et al. 2008; Sun-Edelstein 
and Mauskop 2009).
In the future, further randomized, double-blind con-
trolled studies should be done, specifically with var-
ied dosing to provide evidence for dose dependence, 
a larger number of patients in order to provide for 
higher power, studies of longer length in order to deter-
mine the durability of the response, and inclusion of 
patients with a wide age range. In addition, riboflavin 
should be compared head-to-head with other preven-
tive medications. While prophylaxis with riboflavin may 
not completely ameliorate migraine and may take sev-
eral months to achieve results, this is a low-risk, low-cost 
option with minimal side effects that may be able to 
improve the quality of life for some patients by reducing 
the frequency of migraine.
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